The Guardian reports:
The US has bought up virtually all the stocks for the next three months of one of the two drugs proven to work against Covid-19, leaving none for the UK, Europe or most of the rest of the world. Experts and campaigners are alarmed both by the US unilateral action on remdesivir and the wider implications, for instance in the event of a vaccine becoming available. The Trump administration has already shown that it is prepared to outbid and outmaneuver all other countries to secure the medical supplies it needs for the US.
“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University. “President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. The drug, which was trialed in the Ebola epidemic but failed to work as expected, is under patent to Gilead, which means no other company in wealthy countries can make it.
Read the full article.
— Kaushik Vaidya (@KaushikVaidya) July 1, 2020